Trial Profile
A Randomized, Double-blind, Single-dose, 3-way, Parallel Group, Comparator-controlled, Adaptive Design, Pharmacokinetic, Safety, and Tolerability Study in Healthy Male Volunteers to Evaluate Bioequivalence of CBT124 to Avastin® (EU and US)
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 11 Jul 2018
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Cancer
- Focus Pharmacokinetics
- Sponsors Cipla
- 12 Jul 2016 Status changed from not yet recruiting to recruiting.
- 29 Apr 2016 New trial record